|Mr. Thomas Lingelbach||Chairman of the Management Board, Pres & CEO||733.08k||N/A||1963|
|Mr. Franck Grimaud MBA||Pres, Chief Bus. Officer & Member of Management Board||461.28k||N/A||1967|
|Mr. David Lawrence||Acting Chief Financial Officer||1.3M||N/A||1963|
|Mr. Frederic Jacotot||VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board||350.71k||N/A||1965|
|Dr. Juan-Carlos Jaramillo M.D.||Chief Medical Officer & Member of the Management Board||370.93k||N/A||1971|
|Mr. Perry Celentano||Interim Chief Operating Officer||N/A||N/A||N/A|
|Mr. Joshua Drumm Ph.D.||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Laetitia Bachelot-Fontaine||VP of Global Communications & European Investor Relations||N/A||N/A||N/A|
|Mr. Gerald Strohmaier||VP of Human Resource||N/A||N/A||N/A|
|Mr. Christian Taucher||Head of Global Medical Affairs||N/A||N/A||N/A|
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Valneva SE’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 6; Compensation: 10.